Guardant Health Secured FDA Breakthrough Device Designation for Its Shield Multi-Cancer Detection Test
On June 03, 2025, Guardant Health, Inc., a precision oncology company, reported that the U.S. Food and Drug Administration (FDA) granted breakthrough device designation to its Shield multi-cancer detection (MCD) test. This test, which utilized methylation-based blood analysis, was intended for screening several cancer types, such as bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer in individuals aged 45 or older at average risk.
The breakthrough device designation was granted by the FDA to a limited number of devices w...